The Hemoglobinuria drugs in development market research report provides comprehensive information on the therapeutics under development for Hemoglobinuria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hemoglobinuria. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hemoglobinuria and features dormant and discontinued products.
GlobalData tracks 43 drugs in development for Hemoglobinuria by 33 companies/universities/institutes. The top development phase for Hemoglobinuria is phase i with 16 drugs in that stage. The Hemoglobinuria pipeline has 43 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Hemoglobinuria pipeline products market are: NovelMed Therapeutics, Alexion Pharmaceuticals and Shanghai Argo Pharmaceutical.
The key targets in the Hemoglobinuria pipeline products market include Complement C5, Complement Factor B, and Complement C3.
The key mechanisms of action in the Hemoglobinuria pipeline product include Complement C5 Inhibitor with 19 drugs in Pre-Registration. The Hemoglobinuria pipeline products include six routes of administration with the top ROA being Intravenous and six key molecule types in the Hemoglobinuria pipeline products market including Monoclonal Antibody, and Small Molecule.
Hemoglobinuria overview
Hemoglobinuria is a condition characterized by the presence of free hemoglobin in the urine. Hemoglobin is the protein in red blood cells responsible for transporting oxygen throughout the body. When red blood cells break down, the released hemoglobin can be filtered by the kidneys and appear in the urine, giving it a red or brown color. Hemoglobinuria can result from various conditions, including hemolytic anemia, which includes conditions that cause breakdown of red blood cells, such as autoimmune hemolytic anemia, infections, certain medications, or inherited disorders like sickle cell disease or thalassemia; transfusion reactions, which are incompatibility or adverse reactions to blood transfusions, leading to the destruction of donor red blood cells; rhabdomyolysis, which refers to muscle injury or breakdown from trauma, strenuous exercise, or certain medications, and can release myoglobin (a similar protein to hemoglobin) into the bloodstream, causing hemoglobinuria. Severe cases of malaria can also result in hemolysis (rupture of red blood cells), leading to hemoglobinuria. The main visible symptom of hemoglobinuria is discolored urine—usually red or brown in color. Other associated symptoms may depend on the underlying cause and include fatigue, weakness, jaundice (yellowing of the skin or eyes), abdominal pain, or signs of anemia (pale skin, shortness of breath).
For a complete picture of Hemoglobinuria’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
